<DOC>
	<DOCNO>NCT02148107</DOCNO>
	<brief_summary>It objective MRD trial investigate pharmacokinetics , pharmcodynamics , safety tolerability rise dos BI 691751 treatment period 14 day support clinical development LTA4H-inhibitor . Special emphasis give detect potential effect BI 691751 heart rate .</brief_summary>
	<brief_title>Multiple Rising Oral Doses BI 691751 Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male subject accord investigatorÂ´s assessment , base complete medical history include physical examination , vital sign ( BP ( blood pressure ) , PR ( pulse rate ) , 12lead ECG ( electro cardiogramm ) , clinical laboratory test Age 18 50 year ( incl . ) BMI ( body mass index ) 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Subject able understand communicate German Exclusion criterion : Any find medical examination ( include BP ( blood pressure ) , PR ( pulse rate ) ECG ( electro cardiogramm ) deviate normal judge clinically relevant investigator Pulse rate outside 4580 bpm ( beat per minute ) repeat measurement systolic blood pressure great 140 mmHg , diastolic blood pressure great 90 mm Hg Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract could interfere kinetics trial medication Diseases central nervous system ( epilepsy ) , neurological disorder psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Intake drug long halflife ( 24 h ) within 30 day less 10 halflives respective drug prior administration trial medication Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTc interval Participation another trial investigational drug administer within 60 day prior plan administration trial medication Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke inhouseconfinement Alcohol abuse ( consumption 30 g per day male ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m male ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study Vulnerable subject , e.g . subject keep detention , soldier , employee sponsor clinical research organization , involve study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>